193 related articles for article (PubMed ID: 28540420)
1. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.
Yunokawa M; Yoshida H; Watanabe R; Noguchi E; Shimomura A; Shimoi T; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Cancer Chemother Pharmacol; 2017 Jul; 80(1):127-134. PubMed ID: 28540420
[TBL] [Abstract][Full Text] [Related]
2. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
[TBL] [Abstract][Full Text] [Related]
3. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
Birrell SN; Roder DM; Horsfall DJ; Bentel JM; Tilley WD
J Clin Oncol; 1995 Jul; 13(7):1572-7. PubMed ID: 7602345
[TBL] [Abstract][Full Text] [Related]
4. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
6. Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study.
Paleari L; Rutigliani M; Siri G; Provinciali N; Colombo N; Decensi A
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210157
[TBL] [Abstract][Full Text] [Related]
7. Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate.
Nakayama K; Ishikawa M; Nagai Y; Yaegashi N; Aoki Y; Miyazaki K
Int J Clin Oncol; 2010 Apr; 15(2):179-83. PubMed ID: 20217451
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate.
Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Kanao H; Kondo E; Takeshima N
Arch Gynecol Obstet; 2016 Jan; 293(1):177-181. PubMed ID: 26209972
[TBL] [Abstract][Full Text] [Related]
9. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer--a multicentre, open, controlled, prospectively randomised trial.
von Minckwitz G; Loibl S; Brunnert K; Kreienberg R; Melchert F; Mösch R; Neises M; Schermann J; Seufert R; Stiglmayer R; Stosiek U; Kaufmann M
Eur J Cancer; 2002 Nov; 38(17):2265-71. PubMed ID: 12441263
[TBL] [Abstract][Full Text] [Related]
11. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.
Duska LR; Filiaci VL; Walker JL; Holman LL; Hill EK; Moore RG; Ring KL; Pearl ML; Muller CY; Kushnir CL; Lankes HA; Samuelson MI; Carrick KS; Rajan A; Rodgers WH; Kohn EC; Piekarz R; Leslie KK
Clin Cancer Res; 2021 May; 27(10):2734-2741. PubMed ID: 33766814
[TBL] [Abstract][Full Text] [Related]
12. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
13. [Hormonal therapy for endometrial adenocarcinoma].
Susumu N; Aoki D; Suzuki N; Nozawa S
Gan To Kagaku Ryoho; 2001 Jul; 28(7):934-45. PubMed ID: 11478142
[TBL] [Abstract][Full Text] [Related]
14. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer.
Yamazawa K; Hirai M; Fujito A; Nishi H; Terauchi F; Ishikura H; Shozu M; Isaka K
Hum Reprod; 2007 Jul; 22(7):1953-8. PubMed ID: 17449880
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
Tamauchi S; Kajiyama H; Utsumi F; Suzuki S; Niimi K; Sakata J; Mizuno M; Shibata K; Kikkawa F
J Obstet Gynaecol Res; 2018 Jan; 44(1):151-156. PubMed ID: 29121428
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger.
Ota T; Yoshida M; Kimura M; Kinoshita K
Int J Gynecol Cancer; 2005; 15(4):657-62. PubMed ID: 16014120
[TBL] [Abstract][Full Text] [Related]
17. While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity.
Fiascone S; Danilack VA; Kao MJ; Cohen M; Singh K; Kalife E; Luis C; Lokich E; DiSilvestro P; Robison K
Am J Obstet Gynecol; 2018 Oct; 219(4):381.e1-381.e10. PubMed ID: 30063901
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Rocca A; Farolfi A; Maltoni R; Carretta E; Melegari E; Ferrario C; Cecconetto L; Sarti S; Schirone A; Fedeli A; Andreis D; Pietri E; Ibrahim T; Montalto E; Amadori D
Breast Cancer Res Treat; 2015 Jul; 152(1):57-65. PubMed ID: 26012644
[TBL] [Abstract][Full Text] [Related]
19. Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate.
Mitsushita J; Toki T; Kato K; Fujii S; Konishi I
Gynecol Oncol; 2000 Oct; 79(1):129-32. PubMed ID: 11006045
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E
Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
